Laryngeal Muscles Are Spared in the Dystrophin Deficient mdx Mouse

Thomas, Lisa B.; Joseph, Gayle L.; Adkins, Tracey D.; Andrade, Francisco H.; Stemple, Joseph C.
June 2008
Journal of Speech, Language & Hearing Research;Jun2008, Vol. 51 Issue 3, p586
Academic Journal
Purpose: Duchenne muscular dystrophy (DMD) is caused by the loss of the cytoskeletal protein, dystrophin. The disease leads to severe and progressive skeletal muscle wasting. Interestingly, the disease spares some muscles. The purpose of the study was to determine the effects of dystrophin deficiency on 2 intrinsic laryngeal muscles, the posterior cricoarytenoid and the thyroarytenoid, in the mouse model. Method: Larynges from dystrophin-deficient mdx and normal mice were examined histologically. Results: Results demonstrate that despite the absence of dystrophin in the mdx laryngeal muscles, membrane damage, inflammation, necrosis, and regeneration were not detected in the assays performed. Conclusions: The authors concluded that these muscles are 1 of only a few muscle groups spared in this model of dystrophin deficiency. The muscles may count on intrinsic and adaptive protective mechanisms to cope with the absence of dystrophin. Identifying these protective mechanisms may improve DMD management. The study also highlights the unique aspects of the selected laryngeal skeletal muscles and their dissimilarity to limb skeletal muscle.


Related Articles

  • Metabolic profiles of dystrophin and utrophin expression in mouse models of Duchenne muscular dystrophy Griffin, J.L.; Sang, E.; Evens, T.; Davies, K.; Clarke, K. // FEBS Letters;Oct2002, Vol. 530 Issue 1-3, p109 

    Metabolic profiles from 1H nuclear magnetic resonance spectroscopy have been used to describe both one and two protein systems in four mouse models related to Duchenne muscular dystrophy using the pattern recognition technique partial least squares. Robust statistical models were built for...

  • Removing the Immune Response From Muscular Dystrophy Research. Chamberlain, Jeffrey S // Molecular Therapy;Oct2013, Vol. 21 Issue 10, p1821 

    The article reports on a study which describes the potential development of therapies for Duchenne muscular dystrophy (DMD) using an immunodeficient mouse model. The researchers show an extensive testing of human stem cells via the animal model and methods of delivery without rejecting the donor...

  • Use of imaging biomarkers to assess perfusion and glucose metabolism in the skeletal muscle of dystrophic mice. Ahmad, Nabeel; Welch, Ian; Grange, Robert; Hadway, Jennifer; Dhanvantari, Savita; Hill, David; Ting-Yim Lee; Hoffman, Lisa M. // BMC Musculoskeletal Disorders;2011, Vol. 12 Issue 1, p127 

    Background: Duchenne muscular dystrophy (DMD) is a severe neuromuscular disease that affects 1 in 3500 boys. The disease is characterized by progressive muscle degeneration that results from mutations in or loss of the cytoskeletal protein, dystrophin, from the glycoprotein membrane complex,...

  • Screening of dystrophin gene deletions in Egyptian patients with DMD/BMD muscular dystrophies. Effat, Laila K.; El-Harouni, Ashraf A.; Amr, Khalda S.; El-Minisi, Tarik I.; Abdel Meguid, Nagwa; El-Awady, Mostafa // Disease Markers;2000, Vol. 16 Issue 3/4, p125 

    Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are allelic disorders caused by mutations within the dystrophin gene. Our study has identified 100 Egyptian families collected from the Human Genetics Clinic, National Research Center, Cairo. All cases were subjected to...

  • Dystrophin-deicient large animal models: translational research and exon skipping. Xinran Yu; Bo Bao; Yusuke Echigoya; Toshifumi Yokota // American Journal of Translational Research;Sep2015, Vol. 7 Issue 8, p1314 

    Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disorder caused by mutations in the dystrophin gene. Affecting approximately 1 in 3,600-9337 boys, DMD patients exhibit progressive muscle degeneration leading to fatality as a result of heart or respiratory failure. Despite the...

  • Dystrophin, Utrophin, and Muscular Dystrophy. Karpati, George; Holland, Paul // New England Journal of Medicine;3/2/95, Vol. 332 Issue 9, p612 

    A letter to the editor is presented in response to the article "Absence of Dystrophin and Utrophin in a Boy with Severe Muscular Dystrophy," by M-P Chevron, B. Echenne, and J. Damaille in the October 27, 1994 issue.

  • Dystrophin, Utrophin, and Muscular Dystrophy. Chevron, Marie-Pierre // New England Journal of Medicine;3/2/95, Vol. 332 Issue 9, p612 

    A response by Marie-Pierre Chevron in response to his article on a patient with Duchenne's muscular dystrophy and an absence of dystrophin is presented.

  • Gene Therapy for Muscular Dystrophies: Current Status and Future Prospects. Takeda, S.; Miyagoe-Suzuki, Y. // BioDrugs;2001, Vol. 15 Issue 10, p635 

    Since the identification in 1987 of the gene for Duchenne muscular dystrophy (DMD), research on the molecular pathogenesis of muscular dystrophy has progressed extensively. In particular, discovery of the DMD gene product, dystrophin, led to the identification of dystrophin-associated proteins...

  • Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model. Jahnke, Vanessa E.; Van Der Meulen, Jack H.; Johnston, Helen K.; Ghimbovschi, Svetlana; Partridge, Terrence; Hoffman, Eric P.; Nagaraju, Kanneboyina // Skeletal Muscle;2012, Vol. 2 Issue 1, p16 

    Background: Duchenne muscular dystrophy is a genetic disease involving a severe muscle wasting that is characterized by cycles of muscle degeneration/regeneration and culminates in early death in affected boys. Mitochondria are presumed to be involved in the regulation of myoblast...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics